1. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 
Giuseppe Aprile, Elena Ongaro, Marzia Del Re, Stefania Eufemia Lutrino, Marta Bonotto, Laura Ferrari, Karim Rihawi, Giovanni Gerardo Cardellino, Nicoletta Pella, Romano Danesi, Gianpiero Fasola 
Critical Reviews in Oncology / Hematology 
Volume 95, Issue 2, Pages (August 2015)
DOI: /j.critrevonc
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Angiogenesis signaling pathway: receptors and ligands (A, VEGF-A; B, VEGF-B; C, VEGF-C; D, VEGF-D; E: VEGF-E; eNOS, endothelial nitric oxide synthase; MAPK, mitogen-activated protein kinase; NO, nitric oxide; PIGF, placental growth factor; PLC, phospholipase C; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor).
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
(a) Angiogenesis signaling pathway and promising molecular-targeted therapy for advanced gastric cancer (A, VEGF-A; Ang, angiopoietin; B, VEGF-B; C, VEGF-C; D, VEGF-D; E, VEGF-E; NRP, neuropilin; PIGF, placental growth factor; sVEGFR, soluble vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor). (b) Promising new drugs for advanced gastric cancer and corresponding targets (A, vascular endothelial growth factor A; Ang, angiopoietin VEGFR, vascular endothelial growth factor receptor).
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2015 Elsevier Ireland Ltd Terms and Conditions